SARS-CoV-2 Nano Antibody CDR Design for Low-Cost Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, such as baricitinib and remdesivir, are in clinical trial stages with no specific drugs available, and vaccines take years to develop, while existing antibodies face challenges like immunogenicity and high production costs, limiting their effectiveness and accessibility.
Innovation Solution
Development of a nano antibody with specific CDR and FR sequences (SEQ ID NOs) for SARS-CoV-2 neutralization, produced through a method involving immunization, mRNA extraction, PCR amplification, and phage display library screening, offering high affinity and low production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant fully-humanized monoclonal antibody is used, then neutralizing effect is improved, but production cost increases and immunogenicity problems occur
Solution Approach 1:
The patent extracts only the essential functional regions (CDR1, CDR2, CDR3) from the complete monoclonal antibody structure to create a nano antibody. This extraction eliminates unnecessary parts that contribute to high production costs and immunogenicity while retaining the core neutralizing function against SARS-CoV-2.
Solution Approach 2:
The patent segments the monoclonal antibody into its critical complementarity determining regions (CDRs) and framework regions (FRs), reconstructing a minimal functional unit. This segmentation allows for simplified production and reduced immunogenicity while maintaining therapeutic efficacy.
2Reliability
If vaccine development is pursued, then prevention effectiveness is improved, but time required increases to at least 1-2 years
Solution Approach 1:
The patent applies preliminary action by developing a nano antibody that can be rapidly produced and deployed before vaccine completion. The preclinical validation and standardized production protocol enable immediate clinical application, bypassing the lengthy vaccine development timeline while providing effective prevention and treatment.
3Reliability
If polyclonal antibody plasma is used, then treatment effect is achieved, but quality control difficulty and source limitation occur
Solution Approach 1:
The patent extracts the essential neutralizing function from complex polyclonal antibody plasma by identifying and isolating specific CDR sequences. This creates a standardized nano antibody product with consistent quality and predictable efficacy, eliminating the quality control difficulties associated with heterogeneous polyclonal preparations.
Data Source
AI summary
The present disclosure discloses a nano antibody for neutralizing a toxicity of SARS-CoV-2 and preparation method thereof. The nano antibody comprises a complementarity determining region CDR comprising a CDR1, a CDR2 and a CDR3; an amino acid sequence of the CDR1 is selected from at least one of amino acid sequences shown in SEQ ID NO. 1 and SEQ ID NO. 2; an amino acid sequence of the CDR2 is selected from at least one of amino acid sequences shown in SEQ ID NO. 3, SEQ ID NO. 4, and SEQ ID NO. 5; and an amino acid sequence of the CDR3 is selected from at least one of amino acid sequences shown in any one of SEQ ID NO. 6 to SEQ ID NO. 9. The nano antibody for neutralizing the toxicity of SARS-CoV-2 has the advantages of a small molecular weight, a high affinity with the SARS-CoV-2, a low production cost, and the like.